The US Institute of Health and Research Institute (CDC) said it was keen to assist Bangladesh with its expertise in prioritizing potential anti-COVID 19 vaccine recipients. This issue is likely to emerge as a “big challenge” in the coming days.
Dr. Michael Friedman, Country Director of the Centers for Disease Control and Prevention (CDC) in Dhaka, said this in a recent interview with BSS.
Friedman, a physician and health expert, said it would be difficult for Bangladesh to get more than one million doses of vaccine in the first six months after a vaccine is developed.
He said that despite the success of the immunization process for children, it is important to prioritize who will get the vaccine in the first phase as there is no adult immunization program in Bangladesh.
“Vaccination of children and immunization of adults is not the same thing,” Friedman said, adding that vaccinating a large number of adults would be challenging.
Friedman said Bangladesh could use the opportunity to gain more cooperation to get adequate vaccines in the global competition.
He lauded the capabilities and quality of pharmaceutical companies in Bangladesh, saying there were technical challenges in vaccine production and it was time-consuming to achieve this capability.
Beximco Pharma, Bangladesh’s leading pharmaceutical company, has already signed a memorandum of understanding with the Seram Institute of India to supply 30 million doses of vaccine to Bangladesh.
U.S. experts also suggest that Bangladesh could look for potential vaccines from Russia and China to prevent Covid 19 for its most vulnerable populations.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.